The findings of the
Competition Commission health-market inquiry and the consequent drive to uniform
tariffs, as well as the imminent National Health Insurance (NHI) rollout, continued consolidation of
medical aids and finally the inextricable rise in medial inflation, culminate
in a perfect storm for the sector. Against this backdrop of healthcare reform, medical technology companies are focused more than ever on products that deliver cheaper, faster, more efficient patient care. How do re-imbursement models need to change to facilitate disruptive innovation?
Assessing the impact of NHI and
the Health Market Inquiry on South Africa’s Healthcare Industry;
The New Healthcare
Landscape: After NHI and the HMI: what will the future look like?;
Healthcare innovation in South Africa: hospitals, medical
schemes, primary care markets;
public partnerships: private care involvement in the NHI;
the pharma-care landscape: technology and biotechnology infrastructure,
the pharmaceutical value chain, access to world-class generics and
Innovation in health financing and health delivery;
through blockchain: healthcare on the blockchain
means a whole lot more than streamlined hospital visits;
Venture capital and innovation: what is the state of the
healthcare start-up arena? What funding is available? What role does VC
and PE play?;
and operating models; and
Innovation in medical devices and other technology: against the backdrop of
healthcare reform, medical technology companies are focused more than ever on
products that deliver cheaper, faster, more efficient patient care. How do re-imbursement models need to change to
facilitate disruptive innovation?
Mandisa Maholwana, CEO Nelson Mandela Children's Hospital;
Gavin Bauer, head: Market Access, Sanofi-South Africa;
Dr Ronald Whelan, executive director, Healthforce and Medicare Health;
Dr Eugen Watson, founder, Invenico;
Dr Lynda Toussaint, CEO, Unjani Clinic;
Luke Shankland, COO Aviro Health;
Tanya Vogt, CEO, SAMED (South African medical technology industry association);
Dr Peter Cole, CEO, Lancet;
Dilip Naran, head of solutions at MedeMass & Mediswitch,
divisions of Altron; and
Judy Varndell, consulting, public health sector, Deloitte.
Click here for programme agenda.
Discounts of 20% for bookings of five and more.
There is currently a problem displaying related programmes, please contact support.
There is currently a problem displaying related events, please contact support.
For support please contact us.
We are processing your request, please be patient.